AstraZeneca Sues Andrx Over Toprol-XL Patent

Law360, New York (July 23, 2004, 12:00 AM EDT) -- Drug maker AstraZeneca has filed another lawsuit against Andrx for patent infringement related to Andrx’s plan to market a generic version of hypertension drug Toprol-XL.

The complaint, filed in the U.S. District Court for the District of Delaware, is the result of a Paragraph IV Certification letter submitted by Andrx to AstraZeneca concerning its intent to manufacture and sell Toprol-XL (metoprolol succinate) in the 25 mg dose form, AstraZeneca said.

Generics drug applicants must include with their abbreviated new drug applications (ANDAs) a statement addressing the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.